| 2023年年报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 羟苯磺酸钙胶囊(元) | - | 31,289,731.59 | - | - | 30,575,535.24 |
| 研发服务收入(元) | - | - | 7,940,829.51 | - | 5,372,608.50 |
| 眼用制剂(元) | - | 3,641,479.95 | - | - | 3,386,817.74 |
| 吲达帕胺缓释片(元) | - | 5,435,776.15 | - | - | 7,036,220.13 |
| 化学药品制造(元) | 112,271,005.69 | - | - | 112,894,176.99 | - |
| 医药研发外包(元) | - | - | - | 53,424,526.07 | - |
| 仿制药销售(元) | - | - | 13,408,040.31 | - | - |
| 原料药销售(元) | - | - | 2,957,966.81 | - | - |
| 羟苯磺酸钙原料药(元) | - | 5,586,018.22 | - | - | - |
| 医药合同外包服务(元) | 41,462,096.83 | 17,802,173.01 | - | - | - |
| 其他主营业务(元) | - | - | - | - | 3,305,413.67 |
| 其他(元) | - | - | - | - | 3,305,413.67 |
| 其他药品(元) | - | 2,085,265.13 | - | - | - |
| 营业成本(元) | |||||
| 羟苯磺酸钙胶囊(元) | - | 7,395,050.75 | - | - | 6,167,943.43 |
| 研发服务收入(元) | - | - | - | - | 3,596,252.80 |
| 眼用制剂(元) | - | 2,213,082.36 | - | - | 1,703,758.64 |
| 吲达帕胺缓释片(元) | - | 1,439,110.23 | - | - | 1,556,386.63 |
| 化学药品制造(元) | 38,652,393.66 | - | - | 29,673,773.81 | - |
| 医药研发外包(元) | - | - | - | 14,986,331.93 | - |
| 仿制药销售(元) | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - |
| 羟苯磺酸钙原料药(元) | - | 2,981,018.93 | - | - | - |
| 医药合同外包服务(元) | 15,104,010.18 | 8,122,760.01 | - | - | - |
| 其他主营业务(元) | - | - | - | - | 2,609,148.24 |
| 其他(元) | - | - | - | - | 2,609,148.24 |
| 其他药品(元) | - | 2,584,782.20 | - | - | - |
| 毛利(元) | |||||
| 羟苯磺酸钙胶囊(元) | - | 23,894,680.84 | - | - | 24,407,591.81 |
| 研发服务收入(元) | - | - | - | - | 1,776,355.70 |
| 眼用制剂(元) | - | 1,428,397.59 | - | - | 1,683,059.10 |
| 吲达帕胺缓释片(元) | - | 3,996,665.92 | - | - | 5,479,833.50 |
| 化学药品制造(元) | 73,618,612.03 | - | - | 83,220,403.18 | - |
| 医药研发外包(元) | - | - | - | 38,438,194.14 | - |
| 仿制药销售(元) | - | - | - | - | - |
| 原料药销售(元) | - | - | - | - | - |
| 羟苯磺酸钙原料药(元) | - | 2,604,999.29 | - | - | - |
| 医药合同外包服务(元) | 26,358,086.65 | 9,679,413.00 | - | - | - |
| 其他主营业务(元) | - | - | - | - | 696,265.43 |
| 其他(元) | - | - | - | - | 696,265.43 |
| 其他药品(元) | - | -499,517.07 | - | - | - |
| 毛利率(%) | |||||
| 羟苯磺酸钙胶囊(%) | - | 76.37 | - | - | 79.83 |
| 研发服务收入(%) | - | - | - | - | 33.06 |
| 眼用制剂(%) | - | 39.23 | - | - | 49.69 |
| 吲达帕胺缓释片(%) | - | 73.53 | - | - | 77.88 |
| 化学药品制造(%) | 65.57 | - | - | 73.72 | - |
| 医药研发外包(%) | - | - | - | 71.95 | - |
| 仿制药销售(%) | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - |
| 羟苯磺酸钙原料药(%) | - | 46.63 | - | - | - |
| 医药合同外包服务(%) | 63.57 | 54.37 | - | - | - |
| 其他主营业务(%) | - | - | - | - | 21.06 |
| 其他(%) | - | - | - | - | 21.06 |
| 其他药品(%) | - | -23.95 | - | - | - |
| 收入构成(%) | |||||
| 羟苯磺酸钙胶囊(%) | - | 47.52 | - | - | 57.71 |
| 研发服务收入(%) | - | - | 32.67 | - | 10.14 |
| 眼用制剂(%) | - | 5.53 | - | - | 6.39 |
| 吲达帕胺缓释片(%) | - | 8.26 | - | - | 13.28 |
| 化学药品制造(%) | 73.03 | - | - | 67.88 | - |
| 医药研发外包(%) | - | - | - | 32.12 | - |
| 仿制药销售(%) | - | - | 55.16 | - | - |
| 原料药销售(%) | - | - | 12.17 | - | - |
| 羟苯磺酸钙原料药(%) | - | 8.48 | - | - | - |
| 医药合同外包服务(%) | 26.97 | 27.04 | - | - | - |
| 其他主营业务(%) | - | - | - | - | 6.24 |
| 其他(%) | - | - | - | - | 6.24 |
| 其他药品(%) | - | 3.17 | - | - | - |
| 毛利构成(%) | |||||
| 羟苯磺酸钙胶囊(%) | - | 58.13 | - | - | 70.26 |
| 研发服务收入(%) | - | - | - | - | 5.11 |
| 眼用制剂(%) | - | 3.48 | - | - | 4.84 |
| 吲达帕胺缓释片(%) | - | 9.72 | - | - | 15.77 |
| 化学药品制造(%) | 73.64 | - | - | 68.40 | - |
| 医药研发外包(%) | - | - | - | 31.60 | - |
| 仿制药销售(%) | - | - | - | - | - |
| 原料药销售(%) | - | - | - | - | - |
| 羟苯磺酸钙原料药(%) | - | 6.34 | - | - | - |
| 医药合同外包服务(%) | 26.36 | 23.55 | - | - | - |
| 其他主营业务(%) | - | - | - | - | 2.00 |
| 其他(%) | - | - | - | - | 2.00 |
| 其他药品(%) | - | -1.22 | - | - | - |